Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;40(2):189-193.
doi: 10.1038/s41587-021-00901-y. Epub 2021 Apr 29.

CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells

Affiliations

CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells

Karl Petri et al. Nat Biotechnol. 2022 Feb.

Erratum in

Abstract

Prime editors have been delivered using DNA or RNA vectors. Here we demonstrate prime editing with purified ribonucleoprotein complexes. We introduced somatic mutations in zebrafish embryos with frequencies as high as 30% and demonstrate germline transmission. We also observed unintended insertions, deletions and prime editing guide RNA (pegRNA) scaffold incorporations. In HEK293T and primary human T cells, prime editing with purified ribonucleoprotein complexes introduced desired edits with frequencies of up to 21 and 7.5%, respectively.

PubMed Disclaimer

Conflict of interest statement

Competing Financial Interests Statement

J.K.J. has financial interests in Beam Therapeutics, Chroma Medicine (f/k/a YKY, Inc.), Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, SeQure Dx, Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). K.P. has a financial interest in SeQure Dx, Inc.. L.P. has financial interests in Edilytics, SeQure Dx, Inc. and Excelsior Genomics. K.P. and D.Y.K. are paid consultants to Verve Therapeutics. K.C. is an employee, shareholder, and officer of Edilytics, Inc. J.K.J.’s, L.P.’s, K.C.’s, K.P.’s, and D.Y.K.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in TCR2 and Century Therapeutics, and has served as a consultant for multiple companies involved in cell therapies. The remaining authors declare no competing interests.

Figures

Fig. 1 |
Fig. 1 |. Ribonucleoprotein-mediated prime editing in zebrafish.
a, Schematic illustrating the proposed PE mechanism. b, TGX Stain-free™ gel image showing purification products of N- and C-terminally His-tagged PE2 protein. Magenta arrows indicate the desired protein product. Initial (left panel) and final (right panel) purification (representation of two experiments) are shown. Full-length PE2-His was isolated with higher yield and purity. c, Urea-polyacrylamide gel showing in vitro editing of a dsDNA substrate by the PE2-His protein (lanes 1 and 2; representation of two experiments). Unnicked and unextended oligonucleotide migrates at 51 nts (blue arrows). RT-extended oligonucleotide migrates at 74 or 93 nts (red arrows). Larger extension product (green arrow) potentially represents RT-mediated polymerization of the full pegRNA scaffold (see Supplementary Fig. 2d–e). Red zigzag line, gel cropping boundary (see full gel in Supplementary Fig. 2c). L, ssDNA size ladder. d, Workflow for RNP injections into zebrafish embryos for prime editing. e, Prime editing outcomes at the tyr_1 site using pegRNA with 12-nt PBS, 13-nt RTT and C9E scaffold, PE3 strategy, and incubation at 32 °C. Protospacer adjacent motif (PAM) sequence is shown in bold. Red arrow, prime editor nicking location. The top five alleles with the highest frequencies in each category are shown. 10 embryos were pooled for the experiment. f, Experimental conditions tested at eight zebrafish PE target sites. Specified temperatures denote embryo incubation temperatures. pegPBS10, pegRNA with 10-nt PBS; pegPBS13, pegRNA with 13-nt PBS. g, Ratios of pure PE, impure PE and byproduct frequencies between 32 ºC and 28.5 ºC (left panel), between pegPBS10 and pegPBS13 (middle panel) and between PE3 and PE2 (right panel). Dots represent ratios calculated using the results from eight target sites (Supplementary Fig. 5). The bars represent the median and confidence interval (95%). n=32 different comparisons. h, Pure PE frequencies for eight target sites in zebrafish using pegPBS10 to induce +5 G→C or +5 G→T edits at 32 °C. i, PE2 for specified 5-bp and 10-bp deletions (del). j, PE2 for varying lengths of insertions (ins). (h-j) Dots, individual data points (n=2–6 biologically independent replicates, 5–10 embryos per replicate); Bars, mean; Error bars, ± s.e.m. (only for n >2).
Figure 2 |
Figure 2 |. Germline transmission of prime editor-mediated edits corresponding to human pathogenic variants in zebrafish and RNP-mediated prime editing in human cells.
a, Installation of the tyr P302L mutation (corresponding to human TYR P301L) and the kras G12V mutation (corresponding to human KRAS G12V) in zebrafish using PE2 and PE3 and varying embryo incubation temperatures as noted. The molar ratio of pegRNA:ngRNA in PE3 was 10:1. Dots represent individual data points (PPE, purple; IPE, orange; byproducts, black). Intended edits were +3 C→T and +6 G→T for tyr P302L and kras G12V, respectively (Intended edits are annotated as: edit position (counting from the pegRNA-mediated nick), reference base to edited base.). Bars and error bars represent the mean ± s.e.m. of 3 biologically independent replicates (n=3), where each replicate was a pool of 5–10 embryos. Mean frequencies of impure PE are shown above that of pure PE. b, Top panels show founder (F0) screens for tyr P302L (left) and kras G12V (right). Bottom panels show the fraction of F1 offspring carrying PE induced mutations. c, Wild-type and mutant sequences transmitted through germline by the tyr P302L (top) and kras G12V (bottom) founders. Protospacer adjacent motif (PAM) sequence is shown in bold. RT, reverse transcriptase. d-e, RNP-mediated PE3 editing efficiencies in HEK293T cells (d) and human primary T cells (e). Synthetic pegRNAs/ngRNAs with stabilizing 5’ and 3’ modifications were used. Dots represent individual data points (PPE, purple; IPE, orange; byproducts, black; IPE + byproducts, gray) and bars and error bars represent mean ± s.e.m. (n=3 biologically independent replicates). For prime editor-specified substitution at the FANCF site, impure PE data points are shown above byproduct frequencies. For prime editor-specified insertion and deletion at the HEK3 site, impure PE and byproducts are combined because they cannot always be distinguished (Supplementary Fig. 13).

Comment in

  • Prime editing progress.
    Tang L. Tang L. Nat Methods. 2021 Jun;18(6):592. doi: 10.1038/s41592-021-01188-2. Nat Methods. 2021. PMID: 34099936 No abstract available.

References

    1. Anzalone AV et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157, doi:10.1038/s41586-019-1711-4 (2019). - DOI - PMC - PubMed
    1. Anzalone AV, Koblan LW & Liu DR Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 38, 824–844, doi:10.1038/s41587-020-0561-9 (2020). - DOI - PubMed
    1. Lin Q et al. Prime genome editing in rice and wheat. Nat Biotechnol 38, 582–585, doi:10.1038/s41587-020-0455-x (2020). - DOI - PubMed
    1. Liu Y et al. Efficient generation of mouse models with the prime editing system. Cell Discov 6, 27, doi:10.1038/s41421-020-0165-z (2020). - DOI - PMC - PubMed
    1. Surun D et al. Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors. Genes (Basel) 11, doi:10.3390/genes11050511 (2020). - DOI - PMC - PubMed

Publication types

Substances